\u0130leri evre k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde (aKHDAK) tedavi ba\u015far\u0131s\u0131n\u0131 \u00f6ng\u00f6rmek alan\u0131nda \u00f6nemli geli\u015fmeler ya\u015fan\u0131rken, son d\u00f6nemde yap\u0131lan bir \u00e7al\u0131\u015fma dikkat \u00e7ekiyor. \u00c7in T\u0131p Bilimleri Akademisi\u2019nin Kanser Hastanesi\u2019nde (CHCAMS) ger\u00e7ekle\u015ftirilen yeni bir ara\u015ft\u0131rma, imm\u00fcnoterapide ba\u015far\u0131y\u0131 tahmin etmede g\u00fc\u00e7l\u00fc bir biyobelirte\u00e7 olarak plazma d\u00fczeylerindeki \u00e7\u00f6z\u00fcn\u00fcr CD14 (sCD14) molek\u00fcl\u00fcn\u00fc \u00f6n plana \u00e7\u0131kard\u0131. Bu geli\u015fme, \u00f6zellikle imm\u00fcn kontrol inhibit\u00f6rleri (ICI) ile tedavi g\u00f6ren hastalar\u0131n tedaviye yan\u0131t\u0131n\u0131 \u00f6nceden tahmin etmek isteyen onkologlar i\u00e7in \u00f6nemli bir umut \u0131\u015f\u0131\u011f\u0131 olmay\u0131 hedefliyor.<\/p>\n
Ara\u015ft\u0131rmac\u0131lar, kanser tedavisinde kritik rol oynayan sitokinlerin karma\u015f\u0131k yap\u0131s\u0131n\u0131 anlamak i\u00e7in 41 farkl\u0131 sitokini analiz ederek, kal\u0131c\u0131 klinik fayda (DCB) ile fayda g\u00f6stermeyen (NDB) hastalar aras\u0131ndaki molek\u00fcler farkl\u0131l\u0131klar\u0131 belirlemeyi ama\u00e7lad\u0131lar. Flow floresans tekni\u011fi ile ger\u00e7ekle\u015ftirilen bu analizde, 42 aKHDAK hastas\u0131n\u0131n tedavi \u00f6ncesi plazma \u00f6rnekleri incelendi. Sonu\u00e7lar, ay\u0131rt edici yedi sitokinin varl\u0131\u011f\u0131n\u0131 ortaya koyarken, bunlardan sCD14 molek\u00fcl\u00fc hem klinik anlamda hem de istatistiksel performansta \u00f6ne \u00e7\u0131kt\u0131.<\/p>\n
\u00d6zellikle CD14, CCL27, IL-17A ve TNFR1 molek\u00fclleri, kal\u0131c\u0131 yan\u0131t g\u00f6steren hastalarda anlaml\u0131 derecede y\u00fcksek d\u00fczeylerde tespit edilirken, EGF, CHI3L1 ve CCL5 ise fayda g\u00f6rmeyen hastalarda artm\u0131\u015f olarak bulundu. sCD14, klinik sonu\u00e7lar\u0131 tahmin etmedeki ba\u015far\u0131s\u0131yla dikkat \u00e7ekti ve AUC (E\u011fri Alt\u0131 Alan) de\u011feri 0.84 ile y\u00fcksek do\u011fruluk sa\u011flad\u0131. Bu, sCD14\u2019\u00fcn hasta yan\u0131t\u0131n\u0131 \u00f6nceden bildirmede g\u00fc\u00e7l\u00fc bir parametre oldu\u011funu g\u00f6sterdi.<\/p>\n
\u00c7al\u0131\u015fman\u0131n devam\u0131nda yap\u0131lan fonksiyonel zenginle\u015ftirme analizleri, sCD14 molek\u00fcl\u00fcn\u00fcn inflamatuar yan\u0131t ve MAPK sinyal yollar\u0131yla \u00f6zde\u015fle\u015fti\u011fini ortaya koydu. Bu durum, sCD14\u2019\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin t\u00fcm\u00f6rlere kar\u015f\u0131 tepkisini \u015fekillendiren \u00e7ok y\u00f6nl\u00fc bir rol oynad\u0131\u011f\u0131n\u0131 ve imm\u00fcnoterapinin etkinli\u011fini art\u0131rabilecek potansiyele sahip oldu\u011funu yans\u0131t\u0131yor. T\u00fcm\u00f6rlerin ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden ka\u00e7ma mekanizmalar\u0131n\u0131n \u00f6nemli bir engel oldu\u011fu d\u00fc\u015f\u00fcn\u00fcl\u00fcrse, bu bulgular tedavi stratejilerinde yeni ufuklar a\u00e7\u0131yor.<\/p>\n
sCD14\u2019\u00fcn prognostik de\u011feri yaln\u0131zca ke\u015fif kohortuyla s\u0131n\u0131rl\u0131 kalmad\u0131. \u00c7al\u0131\u015fmada ayr\u0131ca, 109 hastan\u0131n plazma protein d\u00fczeylerinden, 22 hastan\u0131n \u00e7oklu imm\u00fcnfloresan (mIF) y\u00f6ntemiyle yap\u0131lan \u00f6l\u00e7\u00fcmlerine, 403 hastal\u0131k geni\u015f bir NSCLC mRNA veri setine kadar pek \u00e7ok ba\u011f\u0131ms\u0131z veri grubu analiz edildi. T\u00fcm bu farkl\u0131 y\u00f6ntem ve veri setlerinde sCD14\u2019\u00fcn y\u00fcksek seviyeleri, hastalar\u0131n ilerlemesiz sa\u011fkal\u0131m\u0131n\u0131n (PFS) uzamas\u0131 ile anlaml\u0131 bir \u015fekilde ili\u015fkili bulundu.<\/p>\n
Dikkat \u00e7ekici bir di\u011fer nokta, CD14 ifadesinin sadece t\u00fcm\u00f6r mikro\u00e7evresinde de\u011fil, sa\u011fl\u0131kl\u0131 dokularda \u00f6zellikle de akci\u011fer adenokarsinomu ve akci\u011fer skuam\u00f6z h\u00fccreli karsinomunda da y\u00fcksek \u00e7\u0131kmas\u0131yd\u0131. Bu, sCD14\u2019\u00fcn t\u00fcm\u00f6r d\u0131\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6zetiminde de rol oynad\u0131\u011f\u0131n\u0131, sistemik bir ba\u011f\u0131\u015f\u0131kl\u0131k uyan\u0131kl\u0131\u011f\u0131n\u0131n g\u00f6stergesi olabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrerek, imm\u00fcng\u00f6zetim mekanizmalar\u0131n\u0131n potansiyel olarak g\u00fc\u00e7lendirilmesine dair yeni tedavi yakla\u015f\u0131mlar\u0131n\u0131 g\u00fcndeme getiriyor.<\/p>\n
Molek\u00fcler d\u00fczeyde CD14, \u00f6zellikle TLR4 gibi toll-like resept\u00f6rlerinin yard\u0131mc\u0131 bir koresept\u00f6r\u00fc olarak g\u00f6rev yap\u0131yor. Bunlar, patojenlerle ili\u015fkili molek\u00fcler kal\u0131plar\u0131 tan\u0131yarak ba\u011f\u0131\u015f\u0131kl\u0131k tepkisini ba\u015flatan kritik molek\u00fcller. Kanser ba\u011flam\u0131nda, bu TLR-CD14 ekseni inflamasyon sinyallerini aktive ediyor ve t\u00fcm\u00f6r mikro\u00e7evresinde ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin infiltesini ve etkinli\u011fini destekleyerek imm\u00fcnoterapinin etkinli\u011fini art\u0131rabilecek mekanizmalar olu\u015fturuyor.<\/p>\n
Klinik prati\u011fe yans\u0131mas\u0131 a\u00e7\u0131s\u0131ndan, hastalardan kan al\u0131m\u0131 ile kolayca \u00f6l\u00e7\u00fclebilen sCD14 d\u00fczeylerinin imm\u00fcnoterapiden fayda sa\u011flayacak hastalar\u0131n \u00f6nceden belirlenmesinde kullan\u0131lmas\u0131, ciddi yan etkilerle kar\u015f\u0131la\u015fabilecek gereksiz tedavilerin \u00f6n\u00fcne ge\u00e7ebilir. B\u00f6ylece daha ki\u015fiselle\u015ftirilmi\u015f ve etkin tedavi planlar\u0131 geli\u015ftirilebilir, maliyetler d\u00fc\u015f\u00fcr\u00fclebilir. Bu durum, g\u00fcn\u00fcm\u00fczde giderek yayg\u0131nla\u015fan hassas onkoloji yakla\u015f\u0131m\u0131n\u0131n temel ta\u015flar\u0131ndan biri olarak de\u011ferlendirilebilir.<\/p>\n
Bununla birlikte, sCD14\u2019\u00fcn t\u00fcm\u00f6r ba\u011f\u0131\u015f\u0131kl\u0131k d\u00fczenine etkilerini belirleyen molek\u00fcler yolaklar\u0131n tam olarak hangi basamaklarda i\u015fledi\u011fi konusunda hala baz\u0131 bilinmezlikler mevcut. Ayr\u0131ca, programlanm\u0131\u015f \u00f6l\u00fcm-ligand 1 (PD-L1) ekspresyonu ve t\u00fcm\u00f6r mutasyon y\u00fck\u00fc gibi mevcut bilinen prognostik fakt\u00f6rlerle sCD14 aras\u0131ndaki ili\u015fki de hen\u00fcz tam olarak ayd\u0131nlat\u0131lm\u0131\u015f de\u011fil. Bu alandaki \u00e7al\u0131\u015fmalar, biyobelirte\u00e7lerin kombinasyonu ile \u00f6ng\u00f6r\u00fc modellerini geli\u015ftirmeye y\u00f6nelerek hasta se\u00e7imini optimize edebilir.<\/p>\n
\u00c7al\u0131\u015fmada kullan\u0131lan y\u00fcksek teknolojili multiplex imm\u00fcnfloresan y\u00f6ntemi, doku \u00f6rneklerinde birden fazla imm\u00fcn belirteci ayn\u0131 anda ve konumsal olarak analiz edip \u2018t\u00fcm\u00f6r-ba\u011f\u0131\u015f\u0131kl\u0131k aray\u00fcz\u00fc\u2019n\u00fcn detayl\u0131 haritas\u0131n\u0131 \u00e7\u0131karma imkan\u0131 verdi. Bu sayede sadece sCD14 miktar\u0131 de\u011fil, ayn\u0131 zamanda t\u00fcm\u00f6r ile ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin etkile\u015fim alanlar\u0131 da daha iyi analiz edildi. Bu t\u00fcr y\u00f6ntemler, geleneksel tekniklerin \u00f6tesinde \u00e7ok detayl\u0131 molek\u00fcler bilgi sunuyor.<\/p>\n
Y\u00fcksek sCD14 seviyelerinin ilerlemesiz sa\u011fkal\u0131m ile g\u00fc\u00e7l\u00fc ili\u015fkisinin ortaya \u00e7\u0131kmas\u0131, \u00e7\u00f6z\u00fcnebilir ba\u011f\u0131\u015f\u0131kl\u0131k arac\u0131lar\u0131n\u0131n sadece inflamasyon veya t\u00fcm\u00f6r y\u00fck\u00fcn\u00fcn g\u00f6stergesi de\u011fil, aktif ve etkili bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n habercisi olabilece\u011fini g\u00f6sterdi. Bu durum, sitokin ve benzeri molek\u00fcllerin kanserde \u00e7ift y\u00f6nl\u00fc rollerinin ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemindeki karma\u015f\u0131k etkilerinin alt\u0131n\u0131 \u00e7iziyor.<\/p>\n
Genel olarak bu veriler, sCD14\u2019\u00fc temel imm\u00fcnoloji ara\u015ft\u0131rmalar\u0131 ile klinik uygulamay\u0131 birbirine ba\u011flayan etkili bir biyobelirte\u00e7 haline getiriyor. Y\u00fcksek prognostik de\u011feri, kolay \u00f6l\u00e7\u00fclebilir olmas\u0131 ve kritik imm\u00fcn yollarla ili\u015fkisi, onu aKHDAK hastalar\u0131nda imm\u00fcnoterapiyi izlemek ve klinik denemelere dahil etmek i\u00e7in cazip bir aday yap\u0131yor.<\/p>\n
Bu \u00e7al\u0131\u015fma, akci\u011fer kanserinde ba\u011f\u0131\u015f\u0131kl\u0131k ortam\u0131n\u0131 anlama yolunda \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 olarak kabul edilirken; biomarker destekli yakla\u015f\u0131mlar ile hasta sonu\u00e7lar\u0131n\u0131n iyile\u015ftirilmesi y\u00f6n\u00fcnde yeni kap\u0131lar aral\u0131yor. \u0130mm\u00fcnoterapilerin onkolojide giderek artan ba\u015far\u0131s\u0131nda, sCD14 gibi biyobelirte\u00e7lerin entegrasyonu, hastalara \u00f6zg\u00fc tedavi planlar\u0131n\u0131n olu\u015fturulmas\u0131nda kritik rol \u00fcstlenebilir.<\/p>\n
B\u00fcy\u00fck ve \u00e7ok etnik gruplardan olu\u015fan klinik kohortlarda yap\u0131lacak ileri validasyonlar ve ger\u00e7ek d\u00fcnya verileri, sCD14\u2019\u00fcn klinik kullan\u0131m\u0131 i\u00e7in kritik \u00f6neme sahip olacak. Ayn\u0131 zamanda, sCD14\u2019\u00fcn t\u00fcm\u00f6r mikro\u00e7evresini nas\u0131l mod\u00fcle etti\u011fine dair mekanistik \u00e7al\u0131\u015fmalar, kontrol noktas\u0131 blokajlar\u0131 ile sinerjik etkiler yaratabilecek yeni tedavi hedeflerini ortaya \u00e7\u0131karabilir.<\/p>\n
Sonu\u00e7 olarak, tedavi \u00f6ncesi plazma sCD14 d\u00fczeylerinin sa\u011flam bir prognostik g\u00f6stergesi olarak tan\u0131mlanmas\u0131, ileri evre k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde biyobelirte\u00e7 temelli imm\u00fcnoterapi alan\u0131nda yeni bir d\u00f6nemin habercisi konumunda. \u0130lerlemeyi geciktirmede ve hasta se\u00e7imini optimize etmede sundu\u011fu bu avantaj, ba\u011f\u0131\u015f\u0131kl\u0131k ve t\u00fcm\u00f6r etkile\u015fimlerini daha iyi anlamam\u0131z\u0131 sa\u011flayarak hastaya \u00f6zg\u00fc etkin kanser bak\u0131m\u0131na \u00f6nemli katk\u0131lar sunuyor.<\/p>\n
sCD14\u2019\u00fcn prognostik rol\u00fc bu alanda kalmayabilir; imm\u00fcnoterapiye diren\u00e7 mekanizmalar\u0131n\u0131 a\u015fmak veya ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131tlar\u0131n\u0131 art\u0131rmaya y\u00f6nelik kombinasyon tedavilerinde de kritik rol \u00fcstlenebilir. Ara\u015ft\u0131rmac\u0131lar ve klinisyenler, t\u00fcm\u00f6r ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n\u0131n karma\u015f\u0131k yap\u0131s\u0131n\u0131 \u00e7\u00f6zmeye devam ederken, bu t\u00fcr ke\u015fifler akci\u011fer kanseri tedavisinde umut vaat eden yeni yakla\u015f\u0131mlar\u0131 \u015fekillendiriyor.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: \u0130leri evre k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde imm\u00fcnoterapi g\u00f6ren hastalarda prognostik biyobelirte\u00e7lerin tespiti ve \u00f6zellikle plazma \u00e7\u00f6z\u00fcn\u00fcr CD14 (sCD14) seviyelerinin tedavi yan\u0131t\u0131n\u0131 \u00f6ng\u00f6rmedeki rol\u00fc.<\/p>\n Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy<\/p>\n Web References<\/strong>: https:\/\/doi.org\/10.1186\/s12885-025-14148-2<\/p>\n Doi Referans<\/strong>: 10.1186\/s12885-025-14148-2<\/p>\n Resim Credits<\/strong>: Scienmag.com<\/p>\n Anahtar Kelimeler<\/strong>: sCD14, k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanseri, imm\u00fcnoterapi, prognostik biyobelirte\u00e7, sitokinler, imm\u00fcn kontrol inhibit\u00f6rleri, ilerlemesiz sa\u011fkal\u0131m, t\u00fcm\u00f6r mikro\u00e7evresi<\/p>\n","protected":false},"excerpt":{"rendered":" \u0130leri evre k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde (aKHDAK) tedavi ba\u015far\u0131s\u0131n\u0131 \u00f6ng\u00f6rmek alan\u0131nda \u00f6nemli geli\u015fmeler ya\u015fan\u0131rken, son d\u00f6nemde yap\u0131lan bir \u00e7al\u0131\u015fma dikkat \u00e7ekiyor. \u00c7in T\u0131p Bilimleri Akademisi\u2019nin Kanser Hastanesi\u2019nde (CHCAMS) ger\u00e7ekle\u015ftirilen yeni bir ara\u015ft\u0131rma, imm\u00fcnoterapide ba\u015far\u0131y\u0131 tahmin etmede g\u00fc\u00e7l\u00fc bir biyobelirte\u00e7 olarak plazma d\u00fczeylerindeki \u00e7\u00f6z\u00fcn\u00fcr CD14 (sCD14) molek\u00fcl\u00fcn\u00fc \u00f6n plana \u00e7\u0131kard\u0131. Bu geli\u015fme, \u00f6zellikle imm\u00fcn kontrol…<\/p>\n","protected":false},"author":1,"featured_media":3673,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[2725,2721,2724,2723,2722],"tmauthors":[],"class_list":{"0":"post-3672","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-akciger-kanseri-tedavisinde-sitokin-analizi","9":"tag-akciger-kanserinde-immunoterapi-biyobelirtecleri","10":"tag-immunoterapide-prognostik-biyobelirtecler","11":"tag-kucuk-hucre-disi-akciger-kanseri-immun-kontrol-inhibitorleri","12":"tag-plazma-scd14-seviyesi-ve-tedavi-yaniti"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Pretreatment-Plazma-sCD14-Seviyesi-ve-Akciger-Kanseri-Immunoterapisi-Sonuclari-1745448279.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3672"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3672\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3673"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3672"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}